Quetiapine Plus Topiramate or Placebo for Bipolar Mania & Cannabis Use in Adolescents

NCT00393978 Phase 4 COMPLETED Results posted

The objectives of this study are to determine whether this treatment may be useful for reducing cannabis consumption; reducing symptoms of bipolar mania; and weight mitigation therapy for individuals on psychopharmacotherapy.

Details

Lead sponsor	University of Cincinnati
Phase	Phase 4
Status	COMPLETED
Enrolment	75
Start date	2006-11
Completion	2014-03

Conditions

• Bipolar Disorder
• Cannabis-Related Disorder

Interventions

• Quetiapine and placebo
• Quetiapine and Topiramate

Primary outcomes

• Change in Joints Per Week — 16 weeks
  Change in timeline follow-back self-reported of joint equivalents per week from baseline to 16 weeks.
• Change in Percent Days of Cannabis Use Per Week — 16 weeks
  Change in percent days of cannabis use per week from baseline to week 16.

Countries

United States